BLACK DIAMOND THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 814.14 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-03-16
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 68.17K shares.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 102.42K shares.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-06-30 was 536.75K shares, a 1320.06% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-03-31 was 106.81K shares, a 35501.67% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 814.14K shares, a 2036.97% increase from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 38.10K shares, a 44.08% decline from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 68.12K shares, a 71.79% decline from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 241.47K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 68.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | 170.58K shares derived: sum of 2 quarters · filed 2026-03-16 | 707.34K shares derived: sum of 3 quarters · filed 2026-03-16 | 814.14K shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 102.42K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 639.17K shares derived: sum of 2 quarters · filed 2025-11-06 | 745.98K shares 10-Q · filed 2025-11-06 | 745.98K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 536.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 643.56K shares 10-Q · filed 2025-08-07 | 643.56K shares derived: sum of 3 quarters · filed 2025-08-07 | 643.56K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 106.81K shares 10-Q · filed 2025-05-12 | 106.81K shares derived: sum of 2 quarters · filed 2025-05-12 | 106.81K shares derived: sum of 3 quarters · filed 2025-05-12 | 144.60K shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 0.00 shares derived: sum of 2 quarters · filed 2025-03-06 | 37.80K shares derived: sum of 3 quarters · filed 2025-03-06 | 38.10K shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 37.80K shares derived: sum of 2 quarters · filed 2024-11-05 | 38.10K shares 10-Q · filed 2024-11-05 | 38.10K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 37.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 38.10K shares 10-Q · filed 2024-08-06 | 38.10K shares derived: sum of 3 quarters · filed 2024-08-06 | 38.10K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 300.00 shares 10-Q · filed 2024-05-09 | 300.00 shares derived: sum of 2 quarters · filed 2024-05-09 | 300.00 shares derived: sum of 3 quarters · filed 2024-05-09 | 300.00 shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-12 | 0.00 shares derived: sum of 3 quarters · filed 2024-03-12 | 68.12K shares 10-K · filed 2024-03-12 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-06 | 68.12K shares 10-Q · filed 2023-11-06 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | 68.12K shares 10-Q · filed 2023-08-11 | ||
| 2023-03-31 | 68.12K shares 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | 241.47K shares 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |